T1055

Ifosfamide (NSC-109724) alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. Ifosfamide is a synthetic analog of the nitrogen mustard cyclophosphamide with antineoplastic activity. This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes.

Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor and a CDK2 antagonist with an IC50 of 200 nM.

Bithionol sulfoxide (Bithionoloxide) is a compound with inhibitory effects on parasites, suppressing the activity of Schistosoma japonicum and Fasciola hepatica.

Bitopertin R enantiomer (RG1678 R enantiomer) is the R-enantiomer of Bitopertin, a noncompetitive glycine reuptake inhibitor that inhibits glycine uptake at human GlyT1 (IC50: 25 nM).

BIX-01338 hydrate is an inhibitor of histone lysine methyltransferase.

Bixin is an orally active carotenoid that modulates TLR4/NF-κB, Nrf2, and ROS to mitigate high-fat diet-induced cardiac injury in mice and induces apoptosis in A549, HeLa, and MCF-7 cells.

BJE6-106 (B106) is a selective PKCδ inhibitor (IC50 = 0.05 μM) with 1000-fold higher selectivity for PKCδ than PKCα (IC50 = 50 μM). BJE6-106 induces caspase-dependent apoptosis, activates the JNK pathway and H2AX, and can be used to study NRAS-mutated melanoma.

BKI-1369, a bumped kinase inhibitor, enhances hERG-inhibitory activity with an IC50 of 1.52 μM.

BLM-IN-1 is a potent inhibitor of Bloom syndrome protein (BLM) with a KD of 1.81 μM and IC50 of 0.95 μM. It induces DNA damage response, apoptosis, and proliferation arrest in cancer cells.

Blonanserin-D5 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.

Blonanserin-D8 is a deuterium-labeled Blonanserin. Blonanserin (T1180) (AD-5423) is a dopamine D2/5-HT2 receptor antagonist with an atypical antipsychotic effect.

EBET-1055 is a degrader of bromodomain and extra-terminal (BET) proteins, consisting of a BET inhibitor (EBET-590), an E3 ubiquitin ligase ligand, and connectors. It effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC) and also modulates cancer-associated fibroblast (CAF) activity, enhancing all reporter gene activities in organoid co-cultures [1].

(R,R)-VRT-534 is the enantiomer of VRT-534. EBET-1055 is a bromodomain and extra-terminal (BET) PROTAC degrader. It effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). Additionally, EBET-1055 modulates cancer-associated fibroblast (CAF) activity, increasing the activity of all reporter genes in organoid co-cultures.